
-
Verastem Oncology NASDAQ:VSTM Verastem Oncology is a development-stage biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with cancer. The company's pipeline is focused on novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including RAF/MEK inhibition and focal adhesion kinase (FAK) inhibition.
Location: 117 Kendrick St Ste 500, Massachusetts, 02494-2730, US | Website: www.verastem.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
339.6M
Cash
88.82M
Avg Qtr Burn
-26.19M
Short % of Float
23.19%
Insider Ownership
0.61%
Institutional Own.
65.93%
Qtr Updated
12/31/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
COPIKTRA (duvelisib) Details Chronic lymphocytic leukemia, Small lymphocytic lymphoma , Cancer, Follicular lymphoma | Approved Quarterly sales | |
Avutometinib (VS-6766) +/- Defactinib Details Ovarian cancer, Cancer, Low-Grade Serous Ovarian Cancer Big Mover™ Suspected Mover™ Susp. Mover™ | PDUFA Approval decision | |
Avutometinib (VS-6766) + LUMAKRAS (sotorasib) Details Cancer, Non-small cell lung carcinoma | Phase 2 Data readout | |
Avutometinib (VS-6766), + defactinib+gemcitabine/nab-paclitaxel Details First-Line Metastatic Pancreatic Cancer | Phase 1/2 Data readout | |
GFH375 (VS-7375) Details Cancer | Phase 1/2 Initiation | |
Avutometinib(VS-6766) (RAF/MEK Inhibitor) Details Non-small cell lung carcinoma, Cancer | Failed Discontinued | |
Avutometinib (VS-6766) + KRAZATI (adagrasib) Details Non-small cell lung carcinoma, Cancer | Failed Discontinued |